Health and economic impact of the correct diagnosis of transthyretin cardiac amyloidosis in Spain

References

• Garcia-Pavia P, Domínguez F, Gonzalez-Lopez E. Transthyretin amyloid cardiomyopathy. Med Clin (Barc). 2021;156:126–134.
   PubMed Web of Science ®Google Scholar
• González-López E, López-Sainz A, García-Pavía P. Diagnóstico y tratamiento de la amiloidosis cardiaca por transtiretina. Progreso y esperanza. Rev Esp Cardiol. 2017;70:991–1004.
   PubMed Web of Science ®Google Scholar
• Castaño A, Drachman BM, Judge D, et al. Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail Rev. 2015;20:163–178.
   PubMed Web of Science ®Google Scholar
• Salas-Vega S, Iliopoulos O, Mossialos E. Assessment of overall survival, quality of life, and safety benefits associated with new cancer medicines. JAMA Oncol. 2017;3:382–390.
   PubMed Web of Science ®Google Scholar
• Cherny NI, Sullivan R, Dafni U, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European society for medical oncology magnitude of clinical benefit scale (ESMO-MCBS). Ann Oncol. 2015;26:1547–1573.
   PubMed Web of Science ®Google Scholar
• Vyndaqel (tafamidis). Ficha técnica. [ cited 2020 Sept 22]. Available from: https://cima.aemps.es/cima/pdfs/es/ft/11717001/FT_11717001.pdf
   Google Scholar
• TreeAge pro healthcare. [ cited 2020 May 6]. Available from: https://www.treeage.com/shop/treeage-pro-healthcare/
   Google Scholar
• Maurer MS, Schwartz JH, Gundapaneni B, et al.; ATTR-ACT Study Investigators. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379:1007–1016.
   PubMed Web of Science ®Google Scholar
• De Giuli F, Khaw KT, Cowie MR, et al. Incidence and outcome of persons with a clinical diagnosis of heart failure in a general practice population of 696.884 in the United Kingdom. Eur J Heart Fail. 2005;7:295–302.
   PubMed Web of Science ®Google Scholar
• Sayago-Silva I, García-López F, Segovia-Cubero J. Epidemiology of heart failure in Spain over the last 20 years. Rev Esp Cardiol (Engl Ed). 2013;66:649–656.
   PubMed Web of Science ®Google Scholar
• Solomon SD, Rizkala AR, Lefkowitz MP, et al. Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial. Circ Heart Fail. 2018;11:e004962.
   PubMed Web of Science ®Google Scholar
• Carrasco-Sánchez FJ, Páez-Rubio MI, García-Moreno JM, et al. Predictive variables for mortality in elderly patients hospitalized due to heart failure with preserved ejection fraction. Med Clin (Barc). 2013;141:423–429.
   PubMed Web of Science ®Google Scholar
• Petitti DB. Meta-analysis, decisión análisis and cost-effectiveness analysis. Methods for quantitative synthesis in medicine. New York (NY): Oxford University Press; 1994.
   Google Scholar
• Damy T, Kristen AV, Suhr OB, et al. Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the transthyretin amyloidosis outcomes survey (THAOS). Eur Heart J. 2019;ehz173. DOI:https://doi.org/10.1093/eurheartj/ehz173
   Google Scholar
• BotPlus. [ cited 2019 Dec 29]. Available from: https://botplusweb.portalfarma.com/
   Google Scholar
• Delgado JF, Oliva J, Llano M, et al. Costes sanitarios y no sanitarios de personas que padecen insuficiencia cardiaca crónica sintomática en España. Rev Esp Cardiol. 2014;67:643–650.
   PubMed Web of Science ®Google Scholar
• Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2007.
   Google Scholar
• Gray AM, Clarke PM, Wolstenholme JL, et al. Applied methods of cost-effectiveness analysis in health care. Oxford: Oxford University Press; 2012.
   Google Scholar
• Rubio-Terrés C, Rubio-Rodríguez D. Probabilistic Analysis: sensitivity analysis or main result? (Editorial). Pharmacoeconomics. 2016;1:2.
   Google Scholar
• Lane T, Fontana M, Martinez-Naharro A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation. 2019;140:16–26.
   PubMed Web of Science ®Google Scholar
• López-Sainz A, Hernández-Hernández A, González-López E, et al. Perfil clínico y evolución de la amiloidosis cardiaca en un centro español de referencia. Rev Esp Cardiol. 2020. DOI:https://doi.org/10.1016/j.rec.2019.12.020
   Google Scholar
• Oerlemans MIFJ, Rutten KHG, Minnema MC, et al. Cardiac amyloidosis: the need for early diagnosis. Neth Heart J. 2019;27:525–536.
   PubMed Web of Science ®Google Scholar
• Merlini G, Dispenzieri A, Sanchorawala V, et al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Prim IEEE Trans Med Imaging. 2018;4:38.
   Google Scholar
• Falk RH, Alexander KM, Liao R, et al. AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy. J Am Coll Cardiol. 2016;68:1323–1341.
   PubMed Web of Science ®Google Scholar
• Ademi Z, Pfeil AM, Hancock E, et al. Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction. Swiss Med Wkly. 2017;147:w14533.
   PubMed Web of Science ®Google Scholar
• Isla D, De Castro J, Juan O, et al. Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer. Clinicoecon Outcomes Res. 2016;9:31–38.
   PubMed Web of Science ®Google Scholar
• Barge-Caballero G, Vázquez-García R, Barge-Caballero E, et al. Amiloidosis cardíaca por cadenas ligeras y por transtirretina: características clínicas, historia natural y predictores pronósticos. Med Clín (Barc). 2021. DOI:https://doi.org/10.1016/j.medcli.2020.04.031
   Google Scholar
• Kazi DS, Bellows BK, Baron SJ, et al. Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy. Circulation. 2020;141:1214–1224.
   PubMed Web of Science ®Google Scholar
• Rozenbaum MH, Kemner J, Parasuraman B. Letter by rozenbaum et al regarding article, “cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy”. Circulation. 2020;142:e210–e211.
   PubMed Web of Science ®Google Scholar